Lead Therapeutics, Inc.

SAN BRUNO, CA · Founded 2006 · Biotech · Acquired

Intracellular drug delivery technology platform that reduces therapeutic doses by 20-80x through novel delivery mechanisms

Claim this profile

Follows are private to you and power your alerts

Updated · lead.bio

Sector
Biotech
Headquarters
SAN BRUNO, CA
Founded
2006
Latest Form D
$3M, Jun 2009
Total capital
$3M
Federal grants
None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
Private capital raised
$3M
1 Form D · last Jun 2009
209 months since last filing
Federal contracts
None on recordNo federal contract awards found.
Granted patents
0
5 pending

Capital timeline

2009FEDERAL ↑EQUITY ↓Cumulative $3M1st Form D$3M
2009FEDERAL ↑EQUITY ↓Cumulative $3M1st Form D$3M

Latest events

  • Private capital raisedForm D · SEC · 1st filing$3M

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Founders and team

From SEC Form D filings
  • Alain SchreiberDirectorNamed in SEC Form D filings
  • Arthur PappasDirectorNamed in SEC Form D filings
  • David HanabusaExecutive OfficerNamed in SEC Form D filings
  • Leonard PostExecutive Officer, DirectorNamed in SEC Form D filings
  • Peter MyersExecutive Officer, DirectorNamed in SEC Form D filings
  • Shuang QiaoExecutive OfficerNamed in SEC Form D filings

What it has protected

USPTO · 0 granted of 5
  • PendingMethods Of Treating Cancer Using DKK-1-INHIBITORSUSPTOApplication PCTUS2020061773
  • PendingBenzoxazole Carboxamide Inhibitors Of Poly(adp-ribose)polymerase (parp)USPTOApplication PCTUS2009031163
  • PendingNovel Semi-synthetic Glycopeptides As Antibacterial AgentsUSPTOApplication PCTUS2008085716
Show all 5 patent records
  • Methods Of Treating Cancer Using DKK-1-INHIBITORSApplication PCTUS2020061773Pending
  • Benzoxazole Carboxamide Inhibitors Of Poly(adp-ribose)polymerase (parp)Application PCTUS2009031163Pending
  • Novel Semi-synthetic Glycopeptides As Antibacterial AgentsApplication PCTUS2008085716Pending
  • Novel Inhibitors Of Poly(adp-ribose)polymerase (parp)Application PCTUS2008071622Pending
  • Semi-synthetic Glycopeptides With Antibacterial ActivityApplication PCTUS2008062483Pending
  • ABLi Therapeutics, Inc.Similar federal contract value in Biotech · null in contracts
  • ZBiotics CoSimilar federal contract value in Biotech · null in contracts
  • GelMEDIX, Inc.Similar federal contract value in Biotech · null in contracts
  • AptamiR Therapeutics, Inc.Similar federal contract value in Biotech · null in contracts
  • Trethera CorpSimilar federal contract value in Biotech · null in contracts
  • Vascugen, Inc.Similar federal contract value in Biotech · null in contracts

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through . SBIR and STTR awards through .